Jazz Pharmaceuticals top products sales 2022-2023
In 2023, Jazz Pharmaceuticals reported 1.27 billion U.S. dollars in total sales for its oxyabte drug Xywav, while reporting some 184 million U.S. dollars in total sales for the cancer drug Defitelio in the same year. This statistic illustrates the total sales of Jazz Pharmaceuticals' top products in 2022 and 2023. Jazz Pharmaceuticals is a California-originated, but today Ireland-based biopharma company.